Christelle Huguet
Este conteúdo não está disponível em sua língua ainda.
Christelle Huguet is Executive Vice President, Head of R&D at Ipsen. Her relevance to the botulinum toxin industry comes from Ipsen’s research-and-development leadership around neuroscience, external innovation, and development programs.
Her role helps separate Ipsen’s current neurotoxin commercial franchise from the broader development organization that supports neuroscience and pipeline work.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Current organization | Ipsen |
| Current role | Executive Vice President, Head of R&D |
| Industry relevance | Ipsen R&D leadership for neuroscience and development context |
| Relevant company | Ipsen |
| Relevant brand | Dysport |
| Market context | Development and external-innovation context around Ipsen’s specialty-care portfolio, including neuroscience |
Career Notes
Section titled “Career Notes”- Ipsen identifies Huguet as Executive Vice President, Head of R&D.
- Ipsen states that she was appointed Executive Vice President, R&D in September 2023.
- Ipsen describes her role as covering discovery to late-stage development programs across oncology, rare disease, and neuroscience.
- Ipsen also describes neuroscience as central to internal innovation and external partnering, with neurotoxins as a major part of that business.
Development Context
Section titled “Development Context”Huguet matters because Ipsen’s toxin business is not only a marketed Dysport franchise. The company also describes neuroscience and neurotoxins as areas of research, development, manufacturing, commercialization, and external partnering.
That context should be interpreted carefully. A development-leadership role does not imply that every Ipsen pipeline program is approved, commercially available, or clinically comparable with Dysport. Product claims still need product-specific labels, trial records, and regulatory sources.
Activity and Public Context
Section titled “Activity and Public Context”Huguet’s role distinguishes Ipsen’s R&D leadership from its commercial neurotoxin-franchise leadership. She complements Olivia Brown, who anchors the current Global Head of Neurotoxins role.